European Innovation Council

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Palobiofarma is a Spanish biotechnology company based in Barcelona's Science Park, dedicated to the discovery and development of new drugs that target adenosine receptors. The company aims to be a leader in adenosine drug discovery in Europe by focusing on innovative therapies. Palobiofarma specializes in creating selective adenosine receptor modulators, with a particular emphasis on addressing advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, the company is working towards bringing its first marketed drug to the medical community, supporting healthcare professionals in their efforts to treat this challenging disease.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human beings using advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed Alya Red, a suite of simulation tools designed for the medical device and pharmaceutical industries. Utilizing a Software-as-a-Service model, Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients. By integrating high-performance computing, computational biomechanics, and data analysis, ELEM's technology enables biomedical companies and clinicians to improve diagnoses, plan treatments, and optimize drug delivery and medical devices.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human beings using advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed Alya Red, a suite of simulation tools designed for the medical device and pharmaceutical industries. Utilizing a Software-as-a-Service model, Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients. By integrating high-performance computing, computational biomechanics, and data analysis, ELEM's technology enables biomedical companies and clinicians to improve diagnoses, plan treatments, and optimize drug delivery and medical devices.

Abzu is a scientific artificial intelligence company founded in January 2018, with offices in Copenhagen, Denmark, and Barcelona, Spain. The company develops the QLattice, an innovative AI platform that aims to challenge conventional black box AI by providing transparent and explainable models. Abzu's technology is designed to assist pharmaceutical and biotech companies in accelerating drug development processes. By unlocking new disease mechanisms, discovering novel biomarkers, and validating multiple targets simultaneously, Abzu enables these companies to reduce research and development costs and enhance their discovery capabilities. Through its pioneering approach, Abzu inspires data scientists to adopt a more scientific methodology in their work.

SAALG Geomechanics SL, founded in 2016 and based in Barcelona, Spain, specializes in developing software for real-time analysis of ground conditions during civil engineering projects. The company provides advanced geological and numerical services, including numerical model calibrations and characterization of soil and rock parameters through back-analysis and inverse analysis. Its offerings include 2D and 3D geomechanical and geotechnical simulations, primarily focused on applications such as tunnel excavations, large and deep excavations, reinforced earth retaining walls, and wellbore stability analysis. By leveraging machine learning and real-time data analysis technology, SAALG Geomechanics enables construction companies to anticipate potential risks associated with ground movement, thereby optimizing project management, minimizing risks, and enhancing efficiency.

SAALG Geomechanics SL, founded in 2016 and based in Barcelona, Spain, specializes in developing software for real-time analysis of ground conditions during civil engineering projects. The company provides advanced geological and numerical services, including numerical model calibrations and characterization of soil and rock parameters through back-analysis and inverse analysis. Its offerings include 2D and 3D geomechanical and geotechnical simulations, primarily focused on applications such as tunnel excavations, large and deep excavations, reinforced earth retaining walls, and wellbore stability analysis. By leveraging machine learning and real-time data analysis technology, SAALG Geomechanics enables construction companies to anticipate potential risks associated with ground movement, thereby optimizing project management, minimizing risks, and enhancing efficiency.

Aortyx is a pioneering company founded by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona, dedicated to developing innovative endovascular devices for the treatment of vascular diseases. The company specializes in technology that promotes tissue regeneration by closely mimicking the biomechanical environment of the aorta. Its devices are designed to create a favorable environment for cell migration and proliferation, utilizing a bioresorbable platform that closely replicates the natural dynamics of the aorta. This approach aims to enhance the effectiveness of treatments for aortic diseases, providing healthcare professionals with advanced solutions for managing these conditions.

Palobiofarma is a Spanish biotechnology company based in Barcelona's Science Park, dedicated to the discovery and development of new drugs that target adenosine receptors. The company aims to be a leader in adenosine drug discovery in Europe by focusing on innovative therapies. Palobiofarma specializes in creating selective adenosine receptor modulators, with a particular emphasis on addressing advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, the company is working towards bringing its first marketed drug to the medical community, supporting healthcare professionals in their efforts to treat this challenging disease.

Palobiofarma is a Spanish biotechnology company based in Barcelona's Science Park, dedicated to the discovery and development of new drugs that target adenosine receptors. The company aims to be a leader in adenosine drug discovery in Europe by focusing on innovative therapies. Palobiofarma specializes in creating selective adenosine receptor modulators, with a particular emphasis on addressing advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, the company is working towards bringing its first marketed drug to the medical community, supporting healthcare professionals in their efforts to treat this challenging disease.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

X1 Wind is a Barcelona-based company focused on developing innovative floating wind platforms designed for deep-water offshore wind energy. Founded in 2017, the company has engineered a floating system that significantly reduces costs by 50% and weight by 80% compared to traditional floating solutions. Its design minimizes the number of active systems, allowing for simplified installation and maintenance. The platform can be fully assembled at the port and deployed using a small tug boat, enhancing operational efficiency. X1 Wind's technology aims to provide a scalable and sustainable energy solution, contributing to the global transition toward clean and affordable energy while also helping to reduce carbon emissions.

Unblur is a technology company based in Barcelona, Spain, founded in 2015, that focuses on developing AI software for public emergency services, including firefighters, civil protection, and police. Its primary offering is IRIS, a modular software-as-a-service platform designed to enhance incident command. The platform centralizes data and tools, providing incident commanders with real-time situational awareness throughout the various stages of an incident. This capability enables emergency service organizations to improve their operational response and make informed decisions during critical situations, ultimately enhancing coordination among teams and effectiveness in emergency management.

Unblur is a technology company based in Barcelona, Spain, founded in 2015, that focuses on developing AI software for public emergency services, including firefighters, civil protection, and police. Its primary offering is IRIS, a modular software-as-a-service platform designed to enhance incident command. The platform centralizes data and tools, providing incident commanders with real-time situational awareness throughout the various stages of an incident. This capability enables emergency service organizations to improve their operational response and make informed decisions during critical situations, ultimately enhancing coordination among teams and effectiveness in emergency management.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

AEInnova, founded in 2014 at the Autonomous University of Barcelona, specializes in innovative Internet of Things (IoT) solutions for predictive maintenance. The company was established by a team of PhDs and engineers with expertise in microelectronics and various engineering disciplines. AEInnova's flagship product, InduEye, is a fully battery-less and autonomous device that monitors vibrations, steam traps, and thermal conditions, harnessing energy from waste heat, with future versions incorporating solar and wind power. The technology stands out due to its patented innovation, which enhances performance and enables real-time edge computing while utilizing advanced wireless communication standards. AEInnova's devices are employed in diverse sectors, including oil and gas, aluminum, steel, paper, and water treatment, and feature a sophisticated IoT cloud-based dashboard for data analytics and predictive maintenance. The company has received 31 international awards for its contributions to sustainability and innovation and has secured significant investment, including funding from the European Commission. AEInnova is actively engaged in multiple EU R&D projects focused on energy harvesting and IoT technologies.

AEInnova, founded in 2014 at the Autonomous University of Barcelona, specializes in innovative Internet of Things (IoT) solutions for predictive maintenance. The company was established by a team of PhDs and engineers with expertise in microelectronics and various engineering disciplines. AEInnova's flagship product, InduEye, is a fully battery-less and autonomous device that monitors vibrations, steam traps, and thermal conditions, harnessing energy from waste heat, with future versions incorporating solar and wind power. The technology stands out due to its patented innovation, which enhances performance and enables real-time edge computing while utilizing advanced wireless communication standards. AEInnova's devices are employed in diverse sectors, including oil and gas, aluminum, steel, paper, and water treatment, and feature a sophisticated IoT cloud-based dashboard for data analytics and predictive maintenance. The company has received 31 international awards for its contributions to sustainability and innovation and has secured significant investment, including funding from the European Commission. AEInnova is actively engaged in multiple EU R&D projects focused on energy harvesting and IoT technologies.

AEInnova, founded in 2014 at the Autonomous University of Barcelona, specializes in innovative Internet of Things (IoT) solutions for predictive maintenance. The company was established by a team of PhDs and engineers with expertise in microelectronics and various engineering disciplines. AEInnova's flagship product, InduEye, is a fully battery-less and autonomous device that monitors vibrations, steam traps, and thermal conditions, harnessing energy from waste heat, with future versions incorporating solar and wind power. The technology stands out due to its patented innovation, which enhances performance and enables real-time edge computing while utilizing advanced wireless communication standards. AEInnova's devices are employed in diverse sectors, including oil and gas, aluminum, steel, paper, and water treatment, and feature a sophisticated IoT cloud-based dashboard for data analytics and predictive maintenance. The company has received 31 international awards for its contributions to sustainability and innovation and has secured significant investment, including funding from the European Commission. AEInnova is actively engaged in multiple EU R&D projects focused on energy harvesting and IoT technologies.

X1 Wind is a Barcelona-based company focused on developing innovative floating wind platforms designed for deep-water offshore wind energy. Founded in 2017, the company has engineered a floating system that significantly reduces costs by 50% and weight by 80% compared to traditional floating solutions. Its design minimizes the number of active systems, allowing for simplified installation and maintenance. The platform can be fully assembled at the port and deployed using a small tug boat, enhancing operational efficiency. X1 Wind's technology aims to provide a scalable and sustainable energy solution, contributing to the global transition toward clean and affordable energy while also helping to reduce carbon emissions.